Myomo Inc. develops and markets wearable medical robotics for people with neurological disorders and upper-limb paralysis. Its MyoPro product line is a powered upper-limb orthosis that uses non-invasive EMG sensors to support weakened or paralyzed arms in patients with conditions such as stroke, brachial plexus injury, traumatic brain injury, spinal cord injury and other neuromuscular disease or injury.
Company news commonly covers MyoPro orders, insurance authorizations, patient-pipeline trends, revenue from recurring patient sources, market-access relationships with orthotics and prosthetics providers, and product-development updates such as the Myomo Mobile App. Updates also include clinical research evaluating MyoPro, operating results, direct-billing activity, international sales channels and board governance changes.
Myomo (NYSE American: MYO) appointed William "Will" Febbo to its board effective April 14, 2026, to serve until the 2028 annual meeting of stockholders, bringing the board to six directors.
Febbo has 30+ years of healthcare, financial services and technology experience, recently joined Performance Health Systems in February 2026, and previously grew OptimizeRx revenue from $5M to $92M with a five-year CAGR of 41%.
Myomo (NYSE: MYO) reported Q4 2025 revenue of $11.4M and full-year 2025 revenue of $40.9M, a 26% increase versus 2024. Q4 included 241 orders and 42% revenue from recurring patient sources. GAAP net loss was $15.6M for 2025; cash and short-term investments were $18.4M. Management guided 2026 revenue to $43M–$46M and expects reduced cash burn and improved operating leverage while pursuing recurring channels and marketing initiatives.
Myomo (NYSE:MYO) entered its first of several expected network participation agreements with Elevance Health, covering Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans. Agreements will phase in market-by-market through Q2 2026, adding 45 million medical members and bringing covered commercial lives to over 80 million, expanding in-network access to the MyoPro powered arm and hand orthoses and supporting affordability for plan members.
Myomo (NYSE American: MYO) will report fourth quarter and full-year 2025 financial results on Monday, March 9, 2026. Management will host a conference call at 4:30 p.m. Eastern to review results, provide a business update, and answer questions.
Investors may pre-register for dial-in credentials, join by phone, or watch a live webcast and later replay at the company’s investor site.
Myomo (NYSE: MYO) reported Q3 2025 revenue of $10.1M, up 10% year-over-year, driven by 186 MyoPro units and record authorizations/orders (229) in the quarter. Year-to-date revenue was $29.6M, up 44% versus prior year. Gross margin declined to 63.8% (Q3) from 75.4% a year earlier, primarily due to lower ASP, higher material and labor costs, and overhead absorption. Q3 net loss was $3.7M (loss of $0.09/share); adjusted EBITDA was $(2.7)M. The company entered a $17.5M debt facility (Nov 4, 2025) with $12.5M funded and reported pro forma cash of $20.1M as of Sept 30, 2025. Myomo reiterated full‑year 2025 revenue guidance of $40M–$42M.
Myomo (NYSE American: MYO) will report third quarter 2025 financial results on Monday, November 10, 2025. Management will host a conference call at 4:30 p.m. Eastern to review results, provide a business update, and answer questions.
Participants may pre-register to receive a dial-in number and PIN or join by dialing 844-707-6932 (U.S.) or 412-317-9250 (International). A live webcast and replay will be available at https://ir.myomo.com/. A dial-in replay is available until November 24, 2025 at 855-669-9658 (U.S. toll free) or 412-317-0088 (International) using access code 4112515.
Myomo (NYSE American: MYO), a wearable medical robotics company specializing in solutions for neurological disorders and upper-limb paralysis, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
The conference will take place from September 8-10, 2025 at the Lotte New York Palace Hotel. Company executives Paul Gudonis (CEO) and David Henry (CFO) will deliver an on-demand presentation and be available for one-on-one meetings with registered investors.
Myomo (NYSE American: MYO) reported Q2 2025 financial results with revenue of $9.7 million, up 28% year-over-year. The company delivered 178 MyoPro units, a 13% increase, with 56% of revenue from Medicare Part B patients. Average selling price rose 14% to $54,200.
Despite revenue growth, the company faced challenges with lead quality and pipeline conversion, leading to updated 2025 revenue guidance of $40-42 million, down from previous $50-53 million. The company implemented cost-reduction measures, including an 8% workforce reduction, expected to save $2 million over 12 months.
Q2 operating loss widened to $4.6 million from $1.1 million year-over-year, with cash position at $15.5 million as of June 30, 2025. The company expects Q3 2025 revenue between $9.5-10.0 million.
Myomo (NYSE American: MYO), a wearable medical robotics company specializing in solutions for neurological disorders and upper-limb paralysis, has scheduled its Q2 2025 financial results release for August 11, 2025.
The company will host a conference call at 4:30 p.m. Eastern time to discuss results and provide business updates. Participants can pre-register online to receive dial-in credentials, or join directly using U.S. (844-707-6932) or International (412-317-9250) numbers. A webcast replay will be available on the investor relations website, and a dial-in replay will be accessible until August 25, 2025.